Elsevier

Peptides

Volume 15, Issue 5, 1994, Pages 769-775
Peptides

Article
β-Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects

https://doi.org/10.1016/0196-9781(94)90028-0Get rights and content

Abstract

We investigated β-endorphin (BE) content in an HIV-infected cell line and in peripheral blood mononuclear cells (PBM) from HIV-positive subjects. HIV infection increased BE content in HuT78 cell line compared to uninfected cells. Accordingly, BE content was greater in HIV-positive subjects than in healthy controls, both in fresh PBM and in mitogen-stimulated or unstimulated cultured cells. Further, in PHA-stimulated cultures, BE increase was correlated with disease progression. Opioids are known to decrease immune responsiveness in vivo, and it may be that the increased BE concentrations contribute to HIV-associated immune deficiency. In HIV-positive subjects, but not in healthy controls, intracellular BE concentration was positively correlated with PHA-induced PBM proliferation. The latter data suggest an alternative explanation: that the increased BE content represents a paradoxical response of the host in an attempt to balance virus-induced immunodepression. Thus, BE may be important in fine-tuning of the immune response with its up- and downregulation dependent upon differences in immune status.

References (38)

  • A. Catania et al.

    α-melanocyte stimulating hormone in the modulation of host reactions

    Endocr. Rev.

    (1993)
  • F. De Wolf et al.

    Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia

    Br. Med. J.

    (1987)
  • S. Gillis et al.

    Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line

    J. Exp. Med.

    (1980)
  • R.A. Gruters et al.

    Lymphocyte functional analysis in HIV infection: Mechanisms and clinical relevance

  • D.V. Harbour et al.

    Immunoregulatory activity of endogenous opioids

  • C.J. Heijnen et al.

    B-endorphin: Cytokine and neuropeptide

    Immunol. Rev.

    (1991)
  • H.M. Johnson et al.

    Neuroendocrine hormone regulation of in vitro antibody production

  • M.E. Kay et al.

    Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes

    Immunology

    (1990)
  • E. Klein et al.

    Surface IgM-kappa specificity on Burkitt limphoma cell in vivo and derived culture lines

    Cancer Res.

    (1968)
  • Cited by (17)

    • Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine

      2010, Microbes and Infection
      Citation Excerpt :

      The shift to a Th1 pattern plays an important role in the induction of cellular immunity [1]. Previous work has shown that the concentration of β-endorphin, an endogenous opioid in peripheral blood mononuclear cells, increases under conditions in which the Th2 cytokine pattern prevails, such as in cells obtained from human immunodeficiency virus (HIV)-positive subjects [24]. Sacerdote and colleagues have shown that both acute and chronic NLX administration skew the immune system toward a Th1 response [16].

    • Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function

      2008, Brain, Behavior, and Immunity
      Citation Excerpt :

      Studies on heroin addicts have repeatedly shown that the opioid consistently causes immunosuppression (Friedman et al., 2003; Neri et al., 2005; Donahoe and Vlahov, 1998). While the large percentage of infections among injecting drug users is partially related to injection methods and life-style practices, it is now accepted that heroin-induced immunosuppression may contribute as cofactor for several microbial infections, possibly enhancing the progression to AIDS in HIV infected individuals (Barcellini et al., 1994; Friedman et al., 2003; Ugen and Nyland, 2007). On the other hand, both preclinical and clinical studies appear to indicate that not all opioid receptor agonists share the same immunosuppressive properties (Sacerdote, 2006).

    View all citing articles on Scopus
    View full text